REGISTRY EVALUATION OF VITAL INFORMATION FOR VADs IN AMBULATORY LIFE (REVIVAL)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01369407|
Recruitment Status : Completed
First Posted : June 8, 2011
Last Update Posted : September 7, 2018
- Study Details
- Tabular View
- No Results Posted
- How to Read a Study Record
|Condition or disease||Intervention/treatment|
|Congestive Heart Failure||Other: No Intervention|
REVIVAL will establish a prospective, observational, multicenter patient cohort in ambulatory patients with chronic, advanced, systolic heart failure that will provide a greater understanding of their clinical trajectory (rates of hospitalizations, transplantation, MCSD use and death), and of how baseline clinical risk measures are related to prognosis. Within the broader goal of 1) improving prognostic assessment in chronic, ambulatory, advanced systolic heart failure, additional targeted goals are to 2) better inform the selection of appropriate candidates for a future study of a strategy of early LVAD therapy vs. optimal medical management in this population, and 3) determine the feasibility of identifying candidates for such a trial. Therefore, the target population will have known high-risk features for increased mortality and hospitalization (e.g., frequent hospitalization, reduced exercise capacity, elevated BNP or N-terminal proBNP, increased Seattle Heart Failure Model risk score, reduced Heart Failure Survival Score).
The REVIVE-IT Registry (i.e., REVIVAL) is a prospective cohort study to be conducted in up to twenty five (25) participating Clinical Sites in the USA. The study will continue until up to 400 eligible heart failure heart failure subjects have been enrolled (estimated length of accrual is 12 months).
|Study Type :||Observational [Patient Registry]|
|Actual Enrollment :||400 participants|
|Target Follow-Up Duration:||2 Years|
|Official Title:||REVIVE-IT Registry (REVIVAL: Registry Evaluation of Vital Information For VADs in Ambulatory Life)|
|Actual Study Start Date :||July 2015|
|Actual Primary Completion Date :||August 29, 2018|
|Actual Study Completion Date :||August 29, 2018|
Enrolled subjects participate for up to 2 years
Other: No Intervention
Not an interventional study
- To characterize clinical outcomes, quality of life and functional impairment over two (2) years in a population of ambulatory patients on evidence-based therapy with advanced chronic systolic heart failure who may benefit from VAD therapy [ Time Frame: 2 years ]
- To evaluate the relationship between heart failure subject's modeled prognosis, self assessed prognosis, preferences for end of life care and thresholds for considering VAD implant. [ Time Frame: 2 years ]
- To evaluate caregiver burden associated with heart failure subject's measures of heart failure severity, quality of life, functional limitations and with preferences for care and thresholds for considering device implant. [ Time Frame: 2 years. ]
- To determine health-associated costs for heart failure subjects in the registry. [ Time Frame: 2 years. ]
- To provide the REVIVE-IT Registry to the INTERMACS study group to be used in comparative analyses of outcomes of patients treated with medical versus VAD therapy. [ Time Frame: 2 years. ]
- Hospitalization [ Time Frame: 2 years ]Assessed throughout participation
- Stroke [ Time Frame: 2 years ]Assessed throughout participation
- MCSD [ Time Frame: 2 years ]Assessed throughout participation (study endpoint)
- Transplant [ Time Frame: 2 years ]Assessed throughout participation (study endpoint)
- Death [ Time Frame: 2 years ]Assessed throughout participation
Biospecimen Retention: Samples With DNA
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
|Ages Eligible for Study:||18 Years to 80 Years (Adult, Older Adult)|
|Sexes Eligible for Study:||All|
|Accepts Healthy Volunteers:||No|
|Sampling Method:||Non-Probability Sample|
- Chronic systolic heart failure ≥ 12 months.
- NYHA II - IV for at least 45 of the last 60 days.
- Last documented left ventricular ejection fraction ≤ 35% by any imaging modality.
- Age 18 - 80 years.
- Under the care of a cardiologist at study site.
- On appropriate evidenced -based heart failure medications - ACE inhibitor, ARB or sacubitril/valsartan [LCZ-696]; beta blocker; aldosterone antagonist; hydralazine/long-acting nitrate [required of African-American subjects only] for ≥ 3 months absent contraindications or intolerances.
- Has ICD or CRT-D. If CRT-D, present for ≥ 3 months.
Demonstrated advanced heart failure, including any one of the following*:
i. Serum sodium ≤ 135 mEq/L (obtained as an outpatient)** ii. Serum BNP ≥ 750 pg/mL or NT-proBNP ≥ 3000 pg/mL** (obtained as an outpatient) iii. Seattle Heart Failure Model (SHFM) one year predicted survival ≤ 85%** iv. Heart Failure Survival Score (HFSS) ≤ 7.19** v. Peak VO2 ≤ 55% of predicted for age by Wasserman equation or ≤ 14 ml/kg/min, with RER ≥ 1.05*** vi. VE/VC02 slope > 40*** vii. 6 minute walk test (6MWT) distance ≤ 350 m without significant non-cardiac limitation** viii. Currently listed as Heart Transplant Status II due to heart failure limitation
History of one (1) hospitalization (≥ 24 hours) for acute or acute on chronic heart failure in the past year with additional history to include:
i. Serum BNP ≥ 500 pg/mL or NT-proBNP ≥ 2000 pg/mL** (obtained as an outpatient)
History of two (2) hospitalizations (≥ 24 hours) for acute or acute on chronic heart failure in the past year.
* Qualifying measure must be the most recent of that type of measure obtained (i.e., a BNP ≥ 1000 obtained 2 months prior would not qualify the heart failure subject if a more recent BNP was < 1000)
**Using values obtained within the prior 90 days, except for peak VO2 within 365 days
***Obtained within the prior 365 days
- Willingness to continue to receive heart failure care from the enrolling advanced heart failure clinic over the next two (2) years and to come for all scheduled study visits.
12. Written Informed consent given.
- Known serious medical problem other than heart failure that would be expected to limit 2-year survival (≥50% mortality within 2 years from non-heart failure diagnosis).
- Patient is not likely to be compliant with the protocol, in the opinion of the Investigator.
- Currently hospitalized.
- Current use of an intravenous inotrope.
- Primary functional limitation from non-cardiac diagnosis even if not likely to limit survival.
- Chronic hemodialysis or peritoneal dialysis or a serum creatinine value of ≥ 3 mg/dL at time of enrollment.
- Cardiac amyloidosis, cardiac sarcoidosis, constrictive pericardial disease, active myocarditis or congenital heart disease with significant structural abnormality.
- Hypertrophic cardiomyopathy unless dilated LV and no outflow gradient.
- Cardiac conditions that are amenable to surgical or percutaneous procedures (other than VAD or transplant) that would substantially improve prognosis and for which this subject is a reasonable candidate, regardless of whether the procedure will or will not be performed.
- Uncorrected hyperthyroidism or hypothyroidism.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01369407
|Principal Investigator:||Keith Aaronson, MD, MS||University of Michigan|
|Principal Investigator:||Garrick Stewart, MD||Brigham and Women's Hospital|
|Study Chair:||Doug Mann, MD||University of Washington - St. Louis|
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
|Responsible Party:||Keith Aaronson, Bertram Pitt M.D. Collegiate Professor of Cardiovascular Medicine and Professor of Internal Medicine, Medical School, University of Michigan|
|Other Study ID Numbers:||
REVIVE-IT REGISTRY (REVIVAL)
HHSN268201100026C ( Other Grant/Funding Number: NHLBI )
|First Posted:||June 8, 2011 Key Record Dates|
|Last Update Posted:||September 7, 2018|
|Last Verified:||September 2018|
Heart Failure NYHA class III
Advanced heart failure
Systolic Heart Failure